[1]王晶莹,宋泉生,朱静琳,等.辛伐他汀复合聚乳酸修复颅骨极限缺损的实验研究[J].中国微创外科杂志,2009,09(12):1148-1151.
　Wang Jingying,Song Quansheng,Zhu Jinglin,et al.Effect of SimvastatinPolylactic Acid Compound on Critical Calvarial Defect[J].Chinese Journal of Minimally Invasive Surgery,2009,09(12):1148-1151.
点击复制

辛伐他汀复合聚乳酸修复颅骨极限缺损的实验研究()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
09
期数:
2009年12期
页码:
1148-1151
栏目:
实验研究
出版日期:
2009-12-31

文章信息/Info

Title:
Effect of SimvastatinPolylactic Acid Compound on Critical Calvarial Defect
作者:
王晶莹; 宋泉生; 朱静琳; 韩晓光; 杨燕琳①; 陈栎①; 李旭; 宋纯理＊
北京大学第三医院骨科，北京100191
Author(s):
Wang Jingying;  Song Quansheng;  Zhu Jinglin;  et al.
Department of Orthopedics, Peking University Third Hospital, Beijing 100191, China
关键词:
骨缺损修复; 辛伐他汀; 聚乳酸
Keywords:
Bone defect repair; Simvastatin; Polylactic acid
分类号:
R-332
文献标志码:
A
摘要:
目的观察辛伐他汀与聚乳酸复合物修复颅骨极限缺损的效果。方法健康雄性SD大鼠20只，体重（150±10）g。制备直径为10 mm的颅骨全层极限缺损模型。实验动物随机分成2组,每组10只。对照组缺损区单纯植入聚乳酸40 mg；实验组缺损区植入辛伐他汀20 mg,聚乳酸40 mg。术后4周、8周通过大体观察、X线摄片比较颅骨缺损区新骨形成面积占总缺损面积百分比、不脱钙骨组织切片甲苯胺蓝染色观察颅骨缺损的修复情况。结果X线片显示术后8周，实验组大部分骨缺损区显示为不规则的高密度阴影，对照组大部分缺损区域仍为低密度透光影。各组（n=5）颅骨缺损区新骨形成面积占总缺损面积百分比，对照组为27.33%±2.54%，实验组为74.63%±2.42%，两组比较差异有显著性(t=-30148，P=0.000)。不脱钙骨组织切片甲苯胺蓝染色显示，术后4周实验组骨缺损区有少量新骨形成，术后8周实验组骨缺损区被大量骨组织充填；对照组骨缺损区为剩余材料与纤维组织充填,仅在缺损周边有少量新骨形成。结论局部应用辛伐他汀有显著促进成骨的作用，对修复骨缺损具有良好的应用前景。
Abstract:
ObjectiveTo investigate the effect of simvastatinpolylactic acid compound on critical calvarial defects in rats.MethodsTwenty male SD rats (150 g±10 g), were used to establish critical cranial defect (10 mm in diameter) model. The animals were randomly divided into control and experiment groups (10 in each). In the control group, 40 mg of polylactic acid were implanted into the defect area; whereas in the experiment group, simvastatinpolylactic acid compound were used (20 mg simvastatin and 40 mg polylactic acid). Four and eight weeks after the implantation, the defect area of the rats was observed by Xray and toluidine blue staining.ResultsEight weeks after the operation, Xray examination showed highdensity regions in the defect area in the experiment group, while lowdensity regions in the control group. The radiopacity of cranial defects were 27.33%±2.54% in the control group, and 74.63%±2.42% in the experimental group (n=5, t=-30.148, P=0.000).Toluidine blue staining showed a few new bone tissues at 4 weeks and fully filled bone defect at 8 weeks in the experiment group. Meanwhile, in the control group, only a small quantity of new bone tissue could be seen on the edge of the cranial defects.ConclusionLocally implanted simvastainpolylactic acid compound is a promising method for the treatment of bone defect owing to its high osteogenic ability.

参考文献/References:

[1]Schmitz JP,Hollinger JO.The critical size defect as an experimental model for craniomandibulofacial nonunions.Clin Orthop,1986,205:299-308.
[2]de Oliveira RC,de Oliveira FH,Cestari TM,et al.Morphometric evaluation of the repair of criticalsize defects using demineralized bovine bone and autogenous bone grafts in rat calvaria.Clin Oral Implants Res,2008,19(8):749-754.
[3]宋纯理，郭昭庆，马庆军,等.辛伐他汀促进骨髓基质细胞的成骨分化.北京大学学报（医学版）,2003,35(5):533-536.
[4]Song CL,Wang JY,Song QS,et al.Simvastatin induces estrogen receptoralpha (ERα) in murine bone marrow stromal cells.J Bone Miner Metab,2008,26:213-217.
[5]Sibel SR,Esra ED.New addition to the statin’s effect.J Trauma,2007,63:187-191.
[6]Oxlund H,Dalstra M,Andreassen TT,et al.Statin given perorally to adult rats increases cancellous bone mass and compressive strength.Calcif Tissue Int,2001,69:299-304.
[7]Gutierrez GE,Lalka D,Garrett IR,et al.Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations.Osteoporos Int,2006,17:1033-1042.
[8]Ko EK,Jeong SI,Rim NG,et al.In vitro osteogenic differentiation of human mesenchymal stem cells and in vivo bone formation in composite nanofiber meshes.Tissue Eng Part A,2008,14(12):2105-2119.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金资助项目（30300352，30772200）,＊通讯作者，①（北京大学第三临床医学院骨科，北京100191）中心实验室
更新日期/Last Update: 2014-01-08